Orphan drug for Acanthamoeba Keratitis
To develop a safe and effective drug for the treatment of the rare eye disease Acanthamoeba Keratitis.
This debilitating infectious disease is caused by a commonly occurring protozoan and in the absence of treatment can result in blindness. There are currently no approved drugs to treat this disease.
The ODAK project will undertake preclinical and clinical research on the Orphan Drug PHMB (Polyhexanide) with the aim of developing the first approved drug for the treatment of this debilitating disease.
PHMB has received the orphan drug designation (EU/3/07/498) according to EC regulations 141/2000.